Novel Tricyclic α-Alkoxyphenyl Propanoic Acid Derivatives: Dual PPAR α/γ Agonists with Hypolipidemic and Antidiabetic Activity

[14C] and [3H]-labelling of Ragaglitazar

[14C] and [3H]-labelling of Ragaglitazar: A dual acting PPARα and PPARγ agonist with hypolipidemic and anti-diabetic activity

✍ Jesper B. Kristensen; Steen K. Johansen; Jacob S. Valsborg; Lars Martiny; Christ 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 138 KB

## Abstract Currently, Ragaglitazar is being developed as a drug for the treatment of hyperglycaemia and hyperlipidemia in patients with type 2 diabetes. Here, we report the labelling of Ragaglitazar with carbon‐14 and tritium for in vivo and in vitro investigations. Two different carbon‐14 labelle